Tocilizumab for the treatment of steroid refractory graft-versus-host disease.
about
Interleukin-6 blockade in ocular inflammatory diseasesThe Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical OverviewChimeric antigen receptor-modified T cells for acute lymphoid leukemiaInterleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target.Current concepts in the diagnosis and management of cytokine release syndrome.Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levelsAnti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses.Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.Advances in understanding the pathogenesis of graft-versus-host disease.Tocilizumab for steroid refractory acute graft-versus-host diseaseRole of STAT3 in regulatory T lymphocyte plasticity during acute graft-vs.-host-diseaseMouse models in bone marrow transplantation and adoptive cellular therapy.Immunotherapeutic implication of IL-6 blockade.The impact of infection and tissue damage in solid-organ transplantation.More than skin deep? Emerging therapies for chronic cutaneous GVHD.Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.The role of regulatory T cells in the biology of graft versus host disease.Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance.Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Taming inflammation by targeting cytokine signaling: new perspectives in the induction of transplantation tolerance.Next generation treatment of acute graft-versus-host disease.State-of-the-art acute and chronic GVHD treatment.A new alternative therapy in dermatology: tocilizumab.Emerging drugs for graft-versus-host disease.Overcoming immunological barriers in regenerative medicine.Host interleukin 6 production regulates inflammation but not tryptophan metabolism in the brain during murine GVHDExtrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease.Blockade of interleukin-27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing Foxp3 expression.Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft versus host disease: low incidence of lower gastrointestinal tract disease.Fulminant skin GvHD with a cytokine pattern resemblant of cytokine release syndrome successfully treated with multimodal immunosuppression including tocilizumab.Effective use of tocilizumab for the treatment of steroid-refractory gastrointestinal acute graft versus host disease in a child with very high levels of serum interleukin-6.
P2860
Q27011357-3E7E7CD6-4493-4241-885C-5BE185B9B68BQ28066083-0EC8FEB9-CD51-4D6C-9F2E-BBE6018272D8Q29620130-EC781190-2AE4-4568-AC4C-FF15E5F9ADB3Q33774610-AB46168B-6E98-4C31-9812-75BED4BA2FE1Q33886879-07E65671-9D3E-4523-A79E-19B2FEB8D289Q34624143-35791128-87ED-488B-A733-11C0005A5B33Q35553632-D43F4B1C-B622-4FE9-B3B6-92709F28F223Q35724900-F6D98FA1-6CE9-46B0-9E64-29096D4B49B7Q35971439-581ABB63-7718-46D1-A4E0-0F04D1937387Q36422339-368C6256-0F28-4B35-8803-DFC316EBFCD8Q37529686-6EFD1455-574B-4C1D-B0EB-E93BD4080312Q37677563-D263621F-5448-48F5-9B43-F88C930E7FD4Q37965754-FD6DE9C9-F7BC-4B82-86C0-B15C1298D37CQ38013050-0FB037B1-1525-45F5-99DD-774D18BA8F57Q38032083-3CEEA6FA-2ED4-4C8E-92B7-1209785A4111Q38058508-27019C63-AB4A-439E-B5B9-159DF7B8B655Q38066586-E0067B84-00B2-4AA0-8C27-89B9115AC9D0Q38117369-84D43D93-93C5-4732-82FB-9171F6EEF830Q38197519-60E0B5DA-5934-4F02-9011-58273F98F090Q38202009-C2E9B6B3-7C27-455A-B344-AE799C1820F4Q38217596-3077B131-5B0A-4061-9837-EE127BBEA912Q38221028-513FCCCB-68BF-4CBE-A7F3-29495B55FAD3Q38416376-33B6D515-CFF5-41F2-9E67-DBCFDFB1ED03Q38507301-1D6074AB-8EFA-4BBB-9F8F-A5DC58A40DD1Q38786084-60C66A32-D1E0-42B1-9943-281B20870CFEQ39948888-3EB4630D-E70C-46C7-9DCD-F23DF81287A3Q41068175-038708B5-A42E-4E6E-A584-ACA2EECB2DACQ42379668-D980FF5B-BA32-4B57-BB9B-8AD474E77DEDQ42381249-01E0C0DB-4B32-4167-9677-3B3EB3943157Q49912604-F8A38AAA-18E2-4943-A425-E20C82F09330Q53436079-F829A5A0-9FD2-4B52-9F46-0E08B2C2CDABQ53631225-CC558394-B1BE-41AB-A115-AEC85918F20B
P2860
Tocilizumab for the treatment of steroid refractory graft-versus-host disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tocilizumab for the treatment of steroid refractory graft-versus-host disease.
@en
Tocilizumab for the treatment of steroid refractory graft-versus-host disease.
@nl
type
label
Tocilizumab for the treatment of steroid refractory graft-versus-host disease.
@en
Tocilizumab for the treatment of steroid refractory graft-versus-host disease.
@nl
prefLabel
Tocilizumab for the treatment of steroid refractory graft-versus-host disease.
@en
Tocilizumab for the treatment of steroid refractory graft-versus-host disease.
@nl
P2093
P2860
P1476
Tocilizumab for the treatment of steroid refractory graft-versus-host disease.
@en
P2093
Ayman Saad
J Douglas Rizzo
Jeanne Palmer
Kathy Kovatovic
Marcelo Pasquini
Parameswaran Hari
Wael Saber
William R Drobyski
P2860
P304
P356
10.1016/J.BBMT.2011.07.001
P577
2011-07-13T00:00:00Z